Stockscreener 앱 받기
138.04
0.01%
0.02
시간 외 거래:
138.00
-0.04
-0.03%
전일 마감가:
$138.02
열려 있는:
$137.41
하루 거래량:
898.23K
Relative Volume:
0.98
시가총액:
$13.69B
수익:
$2.41B
순이익/손실:
$305.80M
주가수익비율:
46.79
EPS:
2.95
순현금흐름:
$492.20M
1주 성능:
-3.92%
1개월 성능:
-1.67%
6개월 성능:
+28.18%
1년 성능:
+11.03%
1일 변동 폭
$136.51
$140.19
1주일 범위
$133.61
$149.98
52주 변동 폭
$84.23
$154.61
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
NBIX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
138.04 | 13.76B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
144.10 | 63.79B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.23 | 43.49B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.18 | 40.30B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
20.03 | 23.21B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
453.53 | 20.59B | 3.08B | 1.24B | 1.07B | 25.61 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap DownWhat's Next? - MarketBeat
Piper Sandler Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock - MarketBeat
Needham & Company LLC Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Q3 2025 Earnings Call Transcript - Insider Monkey
What data driven models say about Neurocrine Biosciences Inc.’s futureJuly 2025 Gainers & Comprehensive Market Scan Reports - newser.com
Why Neurocrine Biosciences Inc. (NB3) stock could rally stronglyTrade Analysis Report & Weekly High Return Stock Forecasts - newser.com
How to build a dashboard for Neurocrine Biosciences Inc. stockPortfolio Value Summary & High Accuracy Trade Signal Alerts - newser.com
Applying sector rotation models to Neurocrine Biosciences Inc.2025 Volume Leaders & Fast Gain Swing Trade Alerts - newser.com
Neurocrine Biosciences (NBIX): Net Margin Miss Challenges Bullish Earnings Growth Narratives - Yahoo Finance
Will Neurocrine Biosciences Inc. (NB3) stock boost dividends furtherJuly 2025 Market Mood & Momentum Based Trading Ideas - newser.com
Fjarde AP Fonden Fourth Swedish National Pension Fund Sells 8,500 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Bought by Oppenheimer Asset Management Inc. - MarketBeat
Short interest data insights for Neurocrine Biosciences Inc.July 2025 Short Interest & Weekly Breakout Opportunity Watchlist - newser.com
What moving averages say about Neurocrine Biosciences Inc.Market Activity Report & Consistent Profit Trading Strategies - newser.com
Is it time to cut losses on Neurocrine Biosciences Inc.Earnings Recap Summary & Fast Entry High Yield Stock Tips - newser.com
Can Neurocrine Biosciences Inc. stock sustain revenue growthJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - newser.com
Is Neurocrine Biosciences Inc. (NB3) stock vulnerable to rate hikesQuarterly Portfolio Summary & Trade Opportunity Analysis - newser.com
Is Now the Right Time to Reassess Neurocrine Biosciences After Expansion News and Valuation Gaps? - simplywall.st
Neurocrine Biosciences (NBIX): Evaluating Valuation After Q3 Earnings Beat and Pipeline Progress - Yahoo Finance
Neurocrine Biosciences (NASDAQ:NBIX) Issues Earnings Results - MarketBeat
Neurocrine Biosciences Completes Phase 2 Study on NBI-1070770 for Depression - TipRanks
Wedbush Raises Price Target on Neurocrine Biosciences to $149 From $143, Keeps Outperform Rating - MarketScreener
Deutsche Bank Adjusts Neurocrine Biosciences Price Target to $142 From $140, Maintains Hold Rating - MarketScreener
Needham Maintains Neurocrine Biosciences (NBIX) Buy Recommendation - Nasdaq
Morgan Stanley Raises Price Target on Neurocrine Biosciences to $178 From $168, Keeps Overweight Rating - MarketScreener
Sumitomo Mitsui Trust Group Inc. Buys 4,030 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Q3 2025 Earnings Call Transcript - MarketBeat
Neurocrine Biosciences (NBIX) Q3 Earnings and Revenues Top Estimates - sharewise.com
What earnings revisions data tells us about Neurocrine Biosciences Inc.Quarterly Profit Report & Daily Market Momentum Tracking - newser.com
Neurocrine: Q3 Earnings Snapshot - Stamford Advocate
Neurocrine Biosciences Beats Estimates But Wall Street Punishes The Stock - Yahoo Finance
Here's What Key Metrics Tell Us About Neurocrine (NBIX) Q3 Earnings - sharewise.com
Neurocrine Biosciences Tops Q3 Estimates With Growing Sales - Finimize
Neurocrine Biosciences Q3 Adjusted Earnings, Revenue Rise - MarketScreener
Neurocrine Biosciences reports 28% jump in Q3 net sales, EPS beats estimates - MarketScreener
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Reports Q3 Revenue $794.9M, vs. FactSet Est of $746.8M - MarketScreener
Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Posts Q3 Adjusted EPS $2.17 per Share, vs. FactSet Est of $2.07 - MarketScreener
Neurocrine Biosciences shares rise as Q3 earnings, revenue beat expectations - Investing.com
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results - PR Newswire
How big funds are accumulating Neurocrine Biosciences Inc. (NB3) stockPortfolio Gains Summary & Risk Adjusted Buy/Sell Alerts - Fundação Cultural do Pará
What RSI levels show for Neurocrine Biosciences Inc. (NB3) stockJuly 2025 Final Week & Free Weekly Chart Analysis and Trade Guides - newser.com
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Peregrine Capital Management LLC - MarketBeat
Is Neurocrine Biosciences Inc. (NB3) stock a buy during volatile marketsMarket Trend Review & Free Real-Time Volume Trigger Notifications - newser.com
Can Neurocrine Biosciences Inc. stock hit analyst price targetsWeekly Gains Report & Daily Risk Controlled Trade Plans - Fundação Cultural do Pará
Trend Recap: How rising interest rates impact Neurocrine Biosciences Inc. stockWeekly Risk Summary & Fast Entry and Exit Trade Plans - Fundação Cultural do Pará
How risky is Neurocrine Biosciences Inc. stock nowJuly 2025 Intraday Action & Fast Gain Stock Tips - newser.com
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GORMAN KEVIN CHARLES | Director |
Aug 07 '25 |
Sale |
126.41 |
106,322 |
13,440,281 |
514,596 |
0.88%
0.09%
자본화:
|
볼륨(24시간):